1. Generics Bulletin

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Samsung Biologics To Take Full Ownership Of Biosimilars Joint Venture

 
• By Dave Wallace

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Samsung Biologics logo website magnifying glass
Samsung Biologics has taken control of the biosimilars joint venture • Source: Dennis Diatel / Alamy Stock Photo

Samsung Biologics is set to take full control of its Samsung Bioepis joint venture with Biogen, after the pair agreed a deal that will see Samsung Biologics acquire Biogen’s “50% -1” equity stake in a transaction worth up to $2.3bn.

The agreement will see Biogen receive $1bn in cash at closing, with a further $1.25bn “to be deferred over two payments of $812.5m due at the first anniversary and $437.5m due at the second anniversary of the closing of the transaction

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.